Last reviewed · How we verify
APOKYN
At a glance
| Generic name | APOKYN |
|---|---|
| Also known as | apomorphine hydrochloride injection, amomorphine, Apomorphine, APO |
| Sponsor | MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals |
| Drug class | Dopaminergic Agonist |
| Target | D(2) dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Parkinson's disease
Common side effects
- Injection site reaction
- Yawning
- Drowsiness/somnolence
- Dyskinesias
- Dizziness/postural hypotension
- Rhinorrhea
- Nausea and/or vomiting
- Hallucination/confusion
- Edema/swelling of extremities
- Fall
- Arthralgia
- Insomnia
Serious adverse events
- Hemolytic anemia
- Syncope/hypotension/orthostatic hypotension
- Hallucinations/psychotic-like behavior
- Serious adverse reactions after intravenous administration
- Falls
- Nausea and vomiting
- Falling asleep during activities of daily living
Drug interactions
- High Risk QT Prolonging Agents
Key clinical trials
- Interest of Continuous Subcutaneous Apomorphine in Parkinsonian Patients at the End of Life
- Effectiveness of Percutaneous Neuromodulation vs Pharmacological Treatment in Cancer Patients With Anterior Knee Pain (NA)
- SAD Study in Patients With Parkinson's Disease and Motor Fluctuations (PHASE1)
- Clinical Trial of Intranasal Delivery of NT-301 (PHASE1)
- Blinking and Yawning in Epilepsy: The Role of Dopamine (NA)
- Optimistic and Pessimistic Dopamine Signals in the Human Brain: a Mapping and Modelling Study in Health and Parkinson's Disease
- SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment
- Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APOKYN CI brief — competitive landscape report
- APOKYN updates RSS · CI watch RSS
- MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals portfolio CI